ESMO 2023 | CodeBreak 300: sotorasib + panitumumab vs. standard-of-care in chemorefractory KRAS G12C mCRC

Filippo Pietrantonio, MD, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, presented the results of the Phase III CodeBreaK 300 (NCT05198934) trial investigating sotorasib combined with panitumumab versus standard of care (SOC) in patients with chemorefractory KRAS G12C-mutated metastatic colorectal cancer (mCRC). 160 patients were randomly assigned to either sotorasib 960 mg daily with panitumumab (n=53), sotorasib 240 mg daily with panitumumab (n=53), or the investigator’s choice of TAS-102 or regorafenib (n=54). The primary endpoint, progression-free survival (PFS), assessed by blinded independent central review, was significantly better in both sotorasib-panitumumab arms compared to SOC, with the sotorasib 960 mg group showing a 0.49 hazard ratio (HR) and the sotorasib 240 mg group showing a 0.58 HR. The study concluded that sotorasib 960 mg with panitumumab demonstrated clinically meaningful benefits in PFS and key secondary endpoints and was well-tolerated with fewer Grade ≥3 treatment-related adverse events compared to SOC. Overall survival data were immature at the time of the analysis. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.